Latest News

Biotech Co.’s Target Price Over Three Times Current

October 14, 2022 (Investorideas.com Newswire) Expanded interim data from the Phase 2 trial of this biotech’s lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:Latest News